Devices/Recall·openFDA/device

Diagnostica Stago, Inc. — Class II: STA Staclot Protein S, Model/Catalog Number: 00746-Reagent Lot number 273074; qualitativ

MediumPublished Sep 9, 2026· AI-analyzed Sep 14, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Diagnostica Stago, Inc. initiated a Class II recall for STA Staclot Protein S (Lot 273074) due to a positive drift in quality control values. This issue occurs within the reagent's stated four-hour onboard stability period during qualitative and quantitative factor deficiency testing.

Who it affects

This recall affects clinical laboratories utilizing the STA Staclot Protein S assay, specifically those using reagent lot 273074, and personnel responsible for coagulation testing and quality control monitoring.

Why it matters

Positive drift in QC values suggests that results may become increasingly inaccurate as the reagent remains onboard the analyzer, potentially leading to incorrect assessments of Protein S levels. From a regulatory perspective, this indicates a failure of the product to maintain its labeled performance specifications throughout its validated stability window, necessitating a field correction and likely a review of the manufacturing or formulation process for this specific lot.

Practical takeaway

Laboratories should immediately identify and sequester reagent lot 273074. Quality assurance teams should review recent Protein S test results for potential inaccuracies linked to QC drift and ensure that current onboard stability protocols reflect the risks identified in this recall.

FDA source material

Class II. Reason: A positive drift in QC values within the reagent's stated 4-hour onboard stability period was identified. Product: STA Staclot Protein S, Model/Catalog Number: 00746-Reagent Lot number 273074; qualitative and quantitative factor deficiency test. Firm: Diagnostica Stago, Inc. (Parsippany NJ United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.